Comparison of oral vs intravenous etoposide in the management of small‐cell lung cancer: A real‐world, population‐based study – MD Linx

For firstline treatment in smallcell lung cancer (SCLC), researchers assessed whether PO vs IV etoposide is useful in combination with a platinum agent (cisplatin/carboplatin) in this study including 2,066 patients with SCLC. Based on stage, patients were divided as limited disease and extensive disease. Route of etoposide administration, dose reductions and vital status was evaluated in chemotherapy naïve patients receiving one cycle of combination chemotherapy. Findings revealed similar overal…

Click here to view the original article.